{"id":"NCT01469039","sponsor":"Alkermes, Inc.","briefTitle":"A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects With Acute Exacerbation of Schizophrenia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-12","primaryCompletion":"2014-01","completion":"2014-03","firstPosted":"2011-11-10","resultsPosted":"2016-01-22","lastUpdate":"2019-01-30"},"enrollment":623,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"ALKS 9072","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ALKS 9072","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.","primaryOutcome":{"measure":"The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score","timeFrame":"Data collected from baseline to day 85","effectByArm":[{"arm":"Aripiprazole Lauroxil 441 mg","deltaMin":-20.9,"sd":1.39},{"arm":"Aripiprazole Lauroxil 882 mg","deltaMin":-21.8,"sd":1.35},{"arm":"Placebo","deltaMin":-9.8,"sd":1.39}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":84,"countries":["United States","Bulgaria","Malaysia","Philippines","Romania","Russia","South Korea","Ukraine"]},"refs":{"pmids":["27707530","27574838","26517202","26114240","28342578","28712616","28625204","28350572","29179595","39145678","28937706"],"seeAlso":["http://grls.rosminzdrav.ru","http://www.clinicaltrialsregister.eu"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":207},"commonTop":["Insomnia","Akathisia","Headache","Schizophrenia","Anxiety"]}}